Buy4

Lycia Therapeutics, Inc.

LYCA

Total Value

$644.7K

Net $644.7K bought

Filing Date

Oct 30, 2026

5 transactions

Purchases

$644.7K

5 transactions

Trade Summary

On Oct 28, 2026 through Oct 30, 2026, Venrock Healthcare Capital Partners III, L.P., Insider, purchased $644.7K of Lycia Therapeutics, Inc. (LYCA) across 5 transactions. The filing covers Common Stock and reflects net buying of $644.7K. Reported prices ranged from $25.23 to $26.86. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.

Price at the Time of the Trade

LYCA daily price with the insider's purchase marked at $25.78.

Bought in the lower half of the 1-month range · the stock trades 2% higher today.

Price data is delayed and provided for context only — not investment advice.

Insider Information

Name: Venrock Healthcare Capital Partners III, L.P.
Role: Insider
Location: NEW YORK, NY

Filing Details

Filing Date: Oct 30, 2026
Transaction Date: Oct 28, 2026
Accession Number: 0001231919-26-001519
Form Type: 4
Net Trading Amount: $644.7K

Non-Derivative Transactions

Date	Security	Shares	Price	Type	Value
Oct 28, 2026	Common Stock	10,570	$25.23	Purchase	$266.7K
Oct 28, 2026	Common Stock	4,430	$25.97	Purchase	$115.0K
Oct 29, 2026	Common Stock	1,000	$26.33	Purchase	$26.3K
Oct 30, 2026	Common Stock	8,804	$26.27	Purchase	$231.3K
Oct 30, 2026	Common Stock	200	$26.86	Purchase	$5.4K

Want live alerts when Venrock Healthcare Capital Partners III, L.P. trades again?

Download Insider Trades to track LYCA, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.

iOS App Android App

Footnotes

(F1)Consists of (i) 4,804 shares held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"); (ii) 481 shares held by VHCP Co-Investment Holdings III,LLC ("VHCP Co-3"); and (iii) 5,285 shares held by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG").
(F2)The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $24.77 to $25.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
(F3)Consists of (i) 1,762,936 shares held by VHCP3; (ii) 176,435 shares held by VHCP Co-3; (iii) 4,244,642 shares held by VHCP EG; and (iv) 651,790 shares held by Venrock Healthcare Capital Partners XP, L.P. ("VHCP XP").
(F4)VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own the shares held by VHCP3 and VHCP Co-3. Bong Koh and Nimish Shah are the voting members of VHCPM3 and may be deemed to beneficially own these shares. Each of VHCPM3 and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein.
(F5)VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCP EG and may be deemed to beneficially own the shares held by VHCP EG. Bong Koh and Nimish Shah are the voting members of VHCPMEG and may be deemed to beneficially own these shares. Each of VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein.
(F6)VHCP Management XP, LLC ("VHCPMXP") is the general partner of VHCP XP and may be deemed to beneficially own the shares held by VHCP XP. Bong Koh and Nimish Shah are the voting members of VHCPMXP and may be deemed to beneficially own these shares. Each of VHCPMXP and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein.
(F7)Consists of (i) 2,013 shares held by VHCP3; (ii) 202 shares held by VHCP Co-3; and (iii) 2,215 shares held by VHCP EG.
(F8)The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $25.88 to $26.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
(F9)Consists of (i) 1,764,949 shares held by VHCP3; (ii) 176,637 shares held by VHCP Co-3; (iii) 4,246,857 shares held by VHCP EG; and (iv) 651,790 shares held by VHCP XP.
(F10)Consists of (i) 455 shares held by VHCP3; (ii) 45 shares held by VHCP Co-3; and (iii) 500 shares held by VHCP EG.
(F11)The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $26.26 to $26.40 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
(F12)Consists of (i) 1,765,404 shares held by VHCP3; (ii) 176,682 shares held by VHCP Co-3; (iii) 4,247,357 shares held by VHCP EG; and (iv) 651,790 shares held by VHCP XP.
(F13)Consists of (i) 4,001 shares held by VHCP3; (ii) 401 shares held by VHCP Co-3; and (iii) 4,402 shares held by VHCP EG.
(F14)The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $25.70 to $26.64 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
(F15)Consists of (i) 1,769,405 shares held by VHCP3; (ii) 177,083 shares held by VHCP Co-3; (iii) 4,251,759 shares held by VHCP EG; and (iv) 651,790 shares held by VHCP XP.
(F16)Consists of (i) 91 shares held by VHCP3; (ii) 9 shares held by VHCP Co-3; and (iii) 100 shares held by VHCP EG.
(F17)The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $26.84 to $26.87 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
(F18)Consists of (i) 1,769,496 shares held by VHCP3; (ii) 177,092 shares held by VHCP Co-3; (iii) 4,251,859 shares held by VHCP EG; and (iv) 651,790 shares held by VHCP XP.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Venrock Healthcare Capital Partners III, L.P.

(Last)

(First)

(Middle)

C/O VENROCK

7 BRYANT PARK, 23RD FLOOR

(Street)

NEW YORK

10018

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Lycia Therapeutics, Inc. [ LYCA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/28/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/28/2026		P		10,570⁽¹⁾	A	$25.23⁽²⁾	6,835,803⁽³⁾	I	By Funds⁽⁴⁾⁽⁵⁾⁽⁶⁾
Common Stock	10/28/2026		P		4,430⁽⁷⁾	A	$25.97⁽⁸⁾	6,840,233⁽⁹⁾	I	By Funds⁽⁴⁾⁽⁵⁾⁽⁶⁾
Common Stock	10/29/2026		P		1,000⁽¹⁰⁾	A	$26.33⁽¹¹⁾	6,841,233⁽¹²⁾	I	By Funds⁽⁴⁾⁽⁵⁾⁽⁶⁾
Common Stock	10/30/2026		P		8,804⁽¹³⁾	A	$26.27⁽¹⁴⁾	6,850,037⁽¹⁵⁾	I	By Funds⁽⁴⁾⁽⁵⁾⁽⁶⁾
Common Stock	10/30/2026		P		200⁽¹⁶⁾	A	$26.86⁽¹⁷⁾	6,850,237⁽¹⁸⁾	I	By Funds⁽⁴⁾⁽⁵⁾⁽⁶⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

1. Name and Address of Reporting Person^*

Venrock Healthcare Capital Partners III, L.P.

(Last)

(First)

(Middle)

C/O VENROCK

7 BRYANT PARK, 23RD FLOOR

(Street)

NEW YORK

10018

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

VHCP Co-Investment Holdings III, LLC

(Last)

(First)

(Middle)

C/O VENROCK

7 BRYANT PARK, 23RD FLOOR

(Street)

NEW YORK

10018

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

VHCP Management III, LLC

(Last)

(First)

(Middle)

C/O VENROCK

7 BRYANT PARK, 23RD FLOOR

(Street)

NEW YORK

10018

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Venrock Healthcare Capital Partners EG, L.P.

(Last)

(First)

(Middle)

C/O VENROCK

7 BRYANT PARK, 23RD FLOOR

(Street)

NEW YORK

10018

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

VHCP Management EG, LLC

(Last)

(First)

(Middle)

C/O VENROCK

7 BRYANT PARK, 23RD FLOOR

(Street)

NEW YORK

10018

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Venrock Healthcare Capital Partners XP, L.P.

(Last)

(First)

(Middle)

C/O VENROCK

7 BRYANT PARK, 23RD FLOOR

(Street)

NEW YORK

10018

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

VHCP Management XP, LLC

(Last)

(First)

(Middle)

C/O VENROCK

7 BRYANT PARK, 23RD FLOOR

(Street)

NEW YORK

10018

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Koh Bong Y

(Last)

(First)

(Middle)

C/O VENROCK

7 BRYANT PARK, 23RD FLOOR

(Street)

NEW YORK

10018

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Shah Nimish P

(Last)

(First)

(Middle)

C/O VENROCK

7 BRYANT PARK, 23RD FLOOR

(Street)

NEW YORK

10018

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

Explanation of Responses:

1. Consists of (i) 4,804 shares held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"); (ii) 481 shares held by VHCP Co-Investment Holdings III,LLC ("VHCP Co-3"); and (iii) 5,285 shares held by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG").

2. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $24.77 to $25.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.

3. Consists of (i) 1,762,936 shares held by VHCP3; (ii) 176,435 shares held by VHCP Co-3; (iii) 4,244,642 shares held by VHCP EG; and (iv) 651,790 shares held by Venrock Healthcare Capital Partners XP, L.P. ("VHCP XP").

4. VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own the shares held by VHCP3 and VHCP Co-3. Bong Koh and Nimish Shah are the voting members of VHCPM3 and may be deemed to beneficially own these shares. Each of VHCPM3 and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein.

5. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCP EG and may be deemed to beneficially own the shares held by VHCP EG. Bong Koh and Nimish Shah are the voting members of VHCPMEG and may be deemed to beneficially own these shares. Each of VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein.

6. VHCP Management XP, LLC ("VHCPMXP") is the general partner of VHCP XP and may be deemed to beneficially own the shares held by VHCP XP. Bong Koh and Nimish Shah are the voting members of VHCPMXP and may be deemed to beneficially own these shares. Each of VHCPMXP and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein.

7. Consists of (i) 2,013 shares held by VHCP3; (ii) 202 shares held by VHCP Co-3; and (iii) 2,215 shares held by VHCP EG.

8. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $25.88 to $26.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.

9. Consists of (i) 1,764,949 shares held by VHCP3; (ii) 176,637 shares held by VHCP Co-3; (iii) 4,246,857 shares held by VHCP EG; and (iv) 651,790 shares held by VHCP XP.

10. Consists of (i) 455 shares held by VHCP3; (ii) 45 shares held by VHCP Co-3; and (iii) 500 shares held by VHCP EG.

11. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $26.26 to $26.40 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.

12. Consists of (i) 1,765,404 shares held by VHCP3; (ii) 176,682 shares held by VHCP Co-3; (iii) 4,247,357 shares held by VHCP EG; and (iv) 651,790 shares held by VHCP XP.

13. Consists of (i) 4,001 shares held by VHCP3; (ii) 401 shares held by VHCP Co-3; and (iii) 4,402 shares held by VHCP EG.

14. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $25.70 to $26.64 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.

15. Consists of (i) 1,769,405 shares held by VHCP3; (ii) 177,083 shares held by VHCP Co-3; (iii) 4,251,759 shares held by VHCP EG; and (iv) 651,790 shares held by VHCP XP.

16. Consists of (i) 91 shares held by VHCP3; (ii) 9 shares held by VHCP Co-3; and (iii) 100 shares held by VHCP EG.

17. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $26.84 to $26.87 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.

18. Consists of (i) 1,769,496 shares held by VHCP3; (ii) 177,092 shares held by VHCP Co-3; (iii) 4,251,859 shares held by VHCP EG; and (iv) 651,790 shares held by VHCP XP.

	Venrock Healthcare Capital Partners III, L.P., By: VHCP Management III, LLC, Its: General Partner, By: /s/ Sherman G. Souther, Authorized Signatory	10/30/2026
	VHCP Co-Investment Holdings III, LLC, By: VHCP Management III, LLC, Its: Manager, By: /s/ Sherman G. Souther, Authorized Signatory	10/30/2026
	VHCP Management III, LLC, By: /s/ Sherman G. Souther, Authorized Signatory	10/30/2026
	Venrock Healthcare Capital Partners EG, L.P., By: VHCP Management EG, LLC, Its: General Partner, By: /s/ Sherman G. Souther, Authorized Signatory	10/30/2026
	VHCP Management EG, LLC, By: /s/ Sherman G. Souther, Authorized Signatory	10/30/2026
	Venrock Healthcare Capital Partners XP, L.P., By: VHCP Management XP, LLC, Its: General Partner, By: /s/ Sherman G. Souther, Authorized Signatory	10/30/2026
	VHCP Management XP, LLC, By: /s/ Sherman G. Souther, Authorized Signatory	10/30/2026
	Bong Y. Koh, By: /s/ Sherman G. Souther, Attorney-in-Fact	10/30/2026
	Nimish P. Shah, By: /s/ Sherman G. Souther, Attorney-in-Fact	10/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Form 4 as rendered by the SEC from accession 0001231919-26-001519.

Lycia Therapeutics, Inc.

Trade Summary

Price at the Time of the Trade

Company Information

Insider Information

Filing Details

Non-Derivative Transactions

Want live alerts when Venrock Healthcare Capital Partners III, L.P. trades again?

Footnotes

SEC Form 4

SEC Filing

Price at the Time of the Trade

SEC Form 4